Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia

Gerald Salen, K. Von Bergmann, D. Lütjohann, P. Kwiterovich, J. Kane, S. B. Patel, T. Musliner, P. Stein, B. Musser

Research output: Contribution to journalArticle

Abstract

Background - Sitosterolemia is a recessively inherited disorder that results from mutations in either ABCG5 or G8 proteins, with hyperabsorption of dietary sterols and decreased hepatic excretion of plant sterols and cholesterol. As a consequence of markedly elevated plasma and tissue sitosterol and campesterol levels, premature atherosclerosis develops. Methods and Results - In this multicenter, double-blind, randomized, placebo-controlled study, we examined whether treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in patients with sitosterolemia. After a 3-week placebo run-in, 37 patients were randomized to receive placebo (n=7) or ezetimibe 10 mg/d (n=30) for 8 weeks. Sitosterol concentrations decreased by 21% (P

Original languageEnglish (US)
Pages (from-to)966-971
Number of pages6
JournalCirculation
Volume109
Issue number8
DOIs
StatePublished - Mar 2 2004

Fingerprint

Phytosterols
Placebos
Anticholesteremic Agents
Sterols
Atherosclerosis
Cholesterol
Mutation
Ezetimibe
Sitosterolemia
Proteins
gamma-sitosterol
Therapeutics

Keywords

  • Cholesterol
  • Coronary disease
  • Ezetimibe
  • Sitosterolemia

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Salen, G., Von Bergmann, K., Lütjohann, D., Kwiterovich, P., Kane, J., Patel, S. B., ... Musser, B. (2004). Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia. Circulation, 109(8), 966-971. https://doi.org/10.1161/01.CIR.0000116766.31036.03

Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia. / Salen, Gerald; Von Bergmann, K.; Lütjohann, D.; Kwiterovich, P.; Kane, J.; Patel, S. B.; Musliner, T.; Stein, P.; Musser, B.

In: Circulation, Vol. 109, No. 8, 02.03.2004, p. 966-971.

Research output: Contribution to journalArticle

Salen, G, Von Bergmann, K, Lütjohann, D, Kwiterovich, P, Kane, J, Patel, SB, Musliner, T, Stein, P & Musser, B 2004, 'Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia', Circulation, vol. 109, no. 8, pp. 966-971. https://doi.org/10.1161/01.CIR.0000116766.31036.03
Salen G, Von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB et al. Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia. Circulation. 2004 Mar 2;109(8):966-971. https://doi.org/10.1161/01.CIR.0000116766.31036.03
Salen, Gerald ; Von Bergmann, K. ; Lütjohann, D. ; Kwiterovich, P. ; Kane, J. ; Patel, S. B. ; Musliner, T. ; Stein, P. ; Musser, B. / Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia. In: Circulation. 2004 ; Vol. 109, No. 8. pp. 966-971.
@article{935a33d8e88041e69bb94581606608e9,
title = "Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia",
abstract = "Background - Sitosterolemia is a recessively inherited disorder that results from mutations in either ABCG5 or G8 proteins, with hyperabsorption of dietary sterols and decreased hepatic excretion of plant sterols and cholesterol. As a consequence of markedly elevated plasma and tissue sitosterol and campesterol levels, premature atherosclerosis develops. Methods and Results - In this multicenter, double-blind, randomized, placebo-controlled study, we examined whether treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in patients with sitosterolemia. After a 3-week placebo run-in, 37 patients were randomized to receive placebo (n=7) or ezetimibe 10 mg/d (n=30) for 8 weeks. Sitosterol concentrations decreased by 21{\%} (P",
keywords = "Cholesterol, Coronary disease, Ezetimibe, Sitosterolemia",
author = "Gerald Salen and {Von Bergmann}, K. and D. L{\"u}tjohann and P. Kwiterovich and J. Kane and Patel, {S. B.} and T. Musliner and P. Stein and B. Musser",
year = "2004",
month = "3",
day = "2",
doi = "10.1161/01.CIR.0000116766.31036.03",
language = "English (US)",
volume = "109",
pages = "966--971",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients with Sitosterolemia

AU - Salen, Gerald

AU - Von Bergmann, K.

AU - Lütjohann, D.

AU - Kwiterovich, P.

AU - Kane, J.

AU - Patel, S. B.

AU - Musliner, T.

AU - Stein, P.

AU - Musser, B.

PY - 2004/3/2

Y1 - 2004/3/2

N2 - Background - Sitosterolemia is a recessively inherited disorder that results from mutations in either ABCG5 or G8 proteins, with hyperabsorption of dietary sterols and decreased hepatic excretion of plant sterols and cholesterol. As a consequence of markedly elevated plasma and tissue sitosterol and campesterol levels, premature atherosclerosis develops. Methods and Results - In this multicenter, double-blind, randomized, placebo-controlled study, we examined whether treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in patients with sitosterolemia. After a 3-week placebo run-in, 37 patients were randomized to receive placebo (n=7) or ezetimibe 10 mg/d (n=30) for 8 weeks. Sitosterol concentrations decreased by 21% (P

AB - Background - Sitosterolemia is a recessively inherited disorder that results from mutations in either ABCG5 or G8 proteins, with hyperabsorption of dietary sterols and decreased hepatic excretion of plant sterols and cholesterol. As a consequence of markedly elevated plasma and tissue sitosterol and campesterol levels, premature atherosclerosis develops. Methods and Results - In this multicenter, double-blind, randomized, placebo-controlled study, we examined whether treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in patients with sitosterolemia. After a 3-week placebo run-in, 37 patients were randomized to receive placebo (n=7) or ezetimibe 10 mg/d (n=30) for 8 weeks. Sitosterol concentrations decreased by 21% (P

KW - Cholesterol

KW - Coronary disease

KW - Ezetimibe

KW - Sitosterolemia

UR - http://www.scopus.com/inward/record.url?scp=1442335817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442335817&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000116766.31036.03

DO - 10.1161/01.CIR.0000116766.31036.03

M3 - Article

C2 - 14769702

AN - SCOPUS:1442335817

VL - 109

SP - 966

EP - 971

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -